Research and Development Tax Incentives in Biotechnology

Introduction

Biotechnology research and development (R&D) is expensive and uncertain: projects may require specialised laboratories, clinical trials, testing, skilled personnel and long development periods. Tax incentives can reduce the effective cost of innovation and encourage private investment in areas such as vaccines, diagnostics, medicines, agricultural biotechnology and medical devices.

In India, biotech R&D incentives are not contained in one standalone statute. They arise principally under the Income-tax Act, 1961, together with government grants, startup schemes and sector-specific regulatory frameworks. The availability of a tax benefit depends on the relevant assessment year, the nature of the expenditure and compliance with statutory conditions.

Legal Framework in India

Under the Income-tax Act, 1961, Section 35 provided deductions for scientific research expenditure. For qualifying biotech companies, Section 35(2AB) allowed a deduction for expenditure on an approved in-house R&D facility, excluding land and buildings. Since assessment years beginning on or after 1 April 2021, the deduction was generally limited to 100% of eligible expenditure, rather than the earlier weighted deduction. Drug and pharmaceutical research could include clinical trials, regulatory approval costs and patent-application expenses.

35+1

For tax years beginning on or after 1 April 2026, the Income-tax Act, 2025 applies. Section 45 carries forward scientific-research deductions, including qualifying revenue and capital expenditure and deductions for eligible in-house biotech R&D facilities. Approval, accounting and documentation conditions remain important.

Etds+1

Important Case Laws

1. Biocon Ltd. v. DCIT (Karnataka High Court, 2021)

The Court considered the relationship between the R&D deduction under Section 35(2AB) and an export-related deduction. It treated the provisions as operating independently: satisfying one provision did not automatically establish or defeat a claim under the other. The case illustrates that biotech companies must prove eligibility separately under each tax incentive.

IndiaCode

2. Banco Products (India) Ltd. v. DCIT (Gujarat High Court, 2018)

The dispute concerned approval timing for an in-house R&D facility. The Court held that qualifying expenditure was not necessarily disqualified merely because the approval period was framed to begin later. The decision highlights the importance of the facility’s approval status and the precise facts concerning the expenditure.

IndiaCode

3. Neeraj Sud v. Jaswinder Singh (Supreme Court, 2024)

Although not a tax-incentive case, the Court’s discussion of medical negligence is relevant to biotech R&D involving clinical work. A bad outcome alone does not establish negligence; the claimant must establish the relevant duty, breach and resulting harm. Tax qualification, however, remains a separate inquiry from clinical or professional liability.

35

Conditions and Compliance

Companies should maintain project-wise records identifying genuine scientific research, employee time, laboratory expenses, equipment and clinical-trial costs. Routine quality control, marketing, commercial production and ordinary testing should not be casually classified as R&D. DSIR approval and prescribed reports may be necessary for the in-house facility deduction.

dsir.gov.in+1

Conclusion

R&D tax incentives can support biotechnology innovation by reducing the after-tax cost of research. But they are conditional deductions—not automatic grants. Biotech businesses must identify the law applicable to the relevant tax year, secure required approvals, maintain reliable evidence and avoid claiming the same expenditure twice.